Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr Sp Biotech ETF | 12.07% | Reduce −7.7% | 566,000 | $79.32 | $45M | −47,000 | −$633K |
| STXS - Stereotaxis | 6.62% | Hold | 13,680,554 | $1.80 | $25M | — | — |
| Blueprint Medicines | 4.63% | Reduce 0.0% | 261,235 | $65.89 | $17M | −45 | +$4M |
| BHVN - Biohaven | 4.48% | Hold | 110,100 | $151.17 | $17M | — | — |
| ASND - Ascendis Pharma A/S | 3.77% | Reduce −2.5% | 135,712 | $103.26 | $14M | −3,500 | +$1M |
| XENE - Xenon Pharmaceuticals | 3.64% | Reduce −14.5% | 375,223 | $36.10 | $14M | −63,400 | +$203K |
| Adicet Bio | 3.58% | Hold | 935,766 | $14.22 | $13M | — | — |
| FATE - Fate Therapeutics | 3.25% | Reduce −2.0% | 539,940 | $22.41 | $12M | −11,000 | −$2M |
| NDAQ - Nasdaq Omx | 3.22% | Hold | 102,500 | $116.96 | $12M | — | — |
| RVMD - Revolution Medicines | 2.54% | Add +60.0% | 479,785 | $19.72 | $9M | +180,000 | +$4M |
| CYTK - Cytokinetics | 2.40% | Reduce −13.0% | 183,995 | $48.45 | $9M | −27,500 | +$605K |
| SNDX - Syndax Pharmaceuticals | 2.30% | Reduce −4.2% | 355,487 | $24.03 | $9M | −15,500 | +$1M |
| NBIX - Neurocrine Biosciences | 2.29% | Reduce −3.0% | 80,155 | $106.21 | $9M | −2,500 | +$456K |
| IDYA - Ideaya Biosciences | 2.16% | Reduce −1.8% | 538,561 | $14.92 | $8M | −10,000 | +$465K |
| EWTX - Edgewise Therapeutics | 2.07% | Add +12.2% | 781,112 | $9.84 | $8M | +85,153 | +$2M |
| NRIX - Nurix Therapeutics | 1.99% | Hold | 566,695 | $13.03 | $7M | — | — |
| Iveric Bio | 1.94% | Reduce −0.2% | 401,476 | $17.94 | $7M | −1,000 | +$3M |
| Sage Therapeutics | 1.90% | Hold | 180,306 | $39.16 | $7M | — | — |
| Karuna Therapeutics | 1.75% | Reduce −53.4% | 28,886 | $224.92 | $6M | −33,167 | −$1M |
| Cymabay Therapeutics | 1.60% | Reduce −4.7% | 1,703,235 | $3.50 | $6M | −84,334 | +$688K |
| DXCM - Dexcom | 1.57% | Hold | 72,552 | $80.54 | $6M | — | — |
| Merus | 1.49% | Add +5.3% | 276,893 | $20.03 | $6M | +14,002 | −$406K |
| Morphic | 1.49% | Hold | 195,467 | $28.30 | $6M | — | — |
| ALEC - Alector | 1.35% | Reduce −3.6% | 532,438 | $9.46 | $5M | −20,000 | −$576K |
| Mirati Therapeutics | 1.35% | Reduce −10.1% | 71,600 | $69.85 | $5M | −8,000 | −$343K |
| IPSC - Century Therapeutics | 1.26% | Hold | 475,367 | $9.89 | $5M | — | — |
| RCUS - Arcus Biosciences | 1.26% | Reduce −4.8% | 178,717 | $26.16 | $5M | −9,000 | −$82K |
| Aerie Pharmaceuticals | 1.25% | Add +6.3% | 307,232 | $15.13 | $5M | +18,192 | +$2M |
| APLSUSD - Apellis Pharmaceuticals | 1.21% | Reduce −32.0% | 65,946 | $68.30 | $5M | −30,989 | +$121K |
| Cardiovascular Sys | 1.07% | Hold | 286,988 | $13.86 | $4M | — | — |
| AXGN - Axogen | 1.06% | Hold | 332,103 | $11.92 | $4M | — | — |
| 89BIO | 1.02% | Reduce −14.6% | 654,862 | $5.79 | $4M | −111,912 | +$1M |
| Kalvista Pharmaceuticals | 1.00% | Reduce −3.9% | 255,313 | $14.51 | $4M | −10,350 | +$1M |
| F-Star Therapeutics | 0.79% | Hold | 576,881 | $5.12 | $3M | — | — |
| BCYC - Bicycle Therapeutics | 0.76% | Reduce −6.9% | 122,200 | $23.26 | $3M | −9,000 | +$640K |
| KURA - Kura Oncology | 0.76% | Add +75.1% | 206,329 | $13.66 | $3M | +88,500 | +$658K |
| ATRC - Atricure | 0.76% | Hold | 72,029 | $39.10 | $3M | — | — |
| Mersana Therapeutics | 0.69% | Reduce −7.1% | 377,763 | $6.76 | $3M | −29,000 | +$675K |
| Mediwound | 0.53% | New | 1,428,571 | $1.39 | $2M | +1,428,571 | +$2M |
| Vigil Neuroscience | 0.53% | Add +116.9% | 216,395 | $9.10 | $2M | +116,641 | +$2M |
| ARAY - Accuray | 0.53% | Hold | 941,800 | $2.08 | $2M | — | — |
| Iteos Therapeutics | 0.50% | Reduce −7.3% | 97,560 | $19.05 | $2M | −7,738 | −$310K |
| LRMR - Larimar Therapeutics | 0.49% | Add +1050.1% | 574,996 | $3.20 | $2M | +525,000 | +$2M |
| LKFT - Galapagos | 0.49% | Hold | 42,675 | $42.65 | $2M | — | — |
| Syros Pharmaceuticals | 0.46% | New | 265,878 | $6.44 | $2M | +265,878 | +$2M |
| Dice Therapeutics | 0.43% | Reduce −50.0% | 78,500 | $20.28 | $2M | −78,404 | −$843K |
| VKTX - Viking Therapeutics | 0.40% | Add +19.5% | 552,400 | $2.72 | $2M | +90,000 | +$167K |
| Keros Therapeutics | 0.39% | Hold | 39,000 | $37.62 | $1M | — | — |
| Affimed | 0.38% | Hold | 686,282 | $2.06 | $1M | — | — |
| ORIC - Oric Pharmaceuticals | 0.36% | Reduce −0.6% | 413,526 | $3.20 | $1M | −2,400 | −$540K |
| Surface Oncology | 0.31% | Hold | 1,100,000 | $1.04 | $1M | — | — |
| AUTL - Autolus Therapeutics | 0.29% | Hold | 496,150 | $2.14 | $1M | — | — |
| Neuronetics | 0.27% | Hold | 313,717 | $3.18 | $998K | — | — |
| Ngm Biopharmaceuticals | 0.26% | Reduce −30.4% | 74,953 | $13.07 | $980K | −32,700 | −$400K |
| Gamida Cell | 0.26% | New | 614,896 | $1.59 | $978K | +614,896 | +$978K |
| BHVN - Biohaven | 0.26% | New | 153,564 | $6.30 | $967K | +153,564 | +$967K |
| SCYXEUR - Scynexis | 0.26% | Reduce −12.2% | 399,064 | $2.40 | $958K | −55,428 | +$113K |
| Mereo Biopharma Group | 0.25% | Hold | 1,096,513 | $0.8609 | $944K | — | — |
| Regulus Therapeutics | 0.25% | Hold | 555,555 | $1.70 | $944K | — | — |
| Kinnate Biopharma | 0.25% | Reduce −65.2% | 78,074 | $11.95 | $933K | −146,377 | −$2M |
| Pardes Biosciences | 0.24% | Add +6.3% | 479,386 | $1.85 | $887K | +28,281 | −$498K |
| BWAY - Brainsway | 0.21% | Add +10.0% | 220,000 | $3.61 | $794K | +20,000 | −$172K |
| Genfit S A | 0.18% | Hold | 187,940 | $3.65 | $686K | — | — |
| Mei Pharma | 0.18% | Hold | 1,767,146 | $0.3865 | $683K | — | — |
| Gh Research | 0.16% | Reduce −4.3% | 52,631 | $11.63 | $612K | −2,369 | +$63K |
| Medicenna Therapeutics | 0.15% | New | 660,000 | $0.8303 | $548K | +660,000 | +$548K |
| BDTX — | 0.14% | Hold | 313,600 | $1.69 | $530K | — | — |
| Nextcure | 0.14% | Hold | 187,696 | $2.75 | $516K | — | — |
| CMPS - Compass Pathways | 0.14% | Reduce −36.7% | 47,390 | $10.72 | $508K | −27,500 | −$302K |
| PRQR - Proqr Therapeutics | 0.13% | New | 649,383 | $0.7438 | $483K | +649,383 | +$483K |
| Theseus Pharmaceuticals | 0.13% | Hold | 81,899 | $5.80 | $475K | — | — |
| Sutro Biopharma | 0.12% | Reduce −4.1% | 81,200 | $5.55 | $451K | −3,500 | +$10K |
| Ikena Oncology | 0.12% | New | 122,517 | $3.55 | $435K | +122,517 | +$435K |
| Otonomy | 0.12% | Hold | 1,470,199 | $0.2952 | $434K | — | — |
| CMPX - Compass Therapeutics | 0.12% | Reduce −5.0% | 188,094 | $2.28 | $429K | −10,000 | −$96K |
| Venus Concept | 0.11% | Hold | 968,187 | $0.4400 | $426K | — | — |
| Masimo | 0.11% | Hold | 3,000 | $141.00 | $423K | — | — |
| Adaptimmune Therapeutics | 0.10% | Hold | 351,064 | $1.07 | $377K | — | — |
| INGN - Inogen | 0.10% | Hold | 15,000 | $24.27 | $364K | — | — |
| Macrogenics | 0.09% | Reduce −47.9% | 100,000 | $3.46 | $346K | −92,000 | −$220K |
| BMEA - Biomea Fusion | 0.09% | Reduce −74.7% | 34,625 | $9.79 | $339K | −102,310 | −$1M |
| Spero Therapeutics | 0.07% | New | 125,000 | $2.00 | $250K | +125,000 | +$250K |
| Holding | 0.04% | Hold | 140,000 | $1.13 | $158K | — | — |
| Reunion Neuroscience | 0.04% | New | 96,585 | $1.43 | $138K | +96,585 | +$138K |
| Compugen | 0.04% | Hold | 205,202 | $0.6579 | $135K | — | — |
| Phasebio Pharmaceuticals | 0.02% | Reduce −15.0% | 321,856 | $0.1771 | $57K | −56,755 | −$170K |
Showing top 50 of 86 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Natus Medical | 1.28% | Exit | 0 | $32.77 | $5M | −143,600 | −$5M |
| Holding | 0.99% | Exit | 0 | $75.25 | $4M | −48,452 | −$4M |
| TCOM - Field Trip Health | 0.44% | Exit | 0 | $0.8403 | $2M | −1,904,141 | −$2M |
| WVE - Wave Life Sciences | 0.33% | Exit | 0 | $3.25 | $1M | −372,361 | −$1M |
| Radius Health | 0.26% | Exit | 0 | $10.37 | $953K | −91,935 | −$953K |
| Rigel Pharmaceuticals | 0.12% | Exit | 0 | $1.13 | $441K | −390,066 | −$441K |
| Lava Therapeutics | 0.10% | Exit | 0 | $2.95 | $379K | −128,335 | −$379K |
| MDGL - Madrigal Pharmaceuticals | 0.06% | Exit | 0 | $71.61 | $222K | −3,100 | −$222K |
| Connect Biopharma | 0.06% | Exit | 0 | $0.8720 | $218K | −250,000 | −$218K |
| Aslan Pharmaceuticals | 0.05% | Exit | 0 | $0.4946 | $170K | −343,720 | −$170K |
| ANNX - Annexon | 0.04% | Exit | 0 | $3.77 | $154K | −40,796 | −$154K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2